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The current differential access to antiretrovirals (ARVs) may
signal a new feature of the global political economy. For the
first time, a whole class of drugs on the World Health
Organisation (WHO) Essential Drugs list has been priced
beyond the means of the majority of those afflicted by a mass
condition.1 This article argues that this change in the global
context, together with the inevitability of explicitly limiting a
new ARV treatment initiative in South Africa, necessitates a
new approach to rationing health interventions.
Specific objectives of the discussion include: a review of
contemporary public health decision making with respect to
antiretroviral treatment (ART) in South Africa; a review of
traditional approaches to priority setting and rationing more
generally; the proposition of a pragmatic response to the
unique challenge posed by ART in the current South African
context; and an exploration of some of the issues resulting from
this response, including how it reconciles with human rights
approaches, and the societal value judgements that are
required.  Finally, a response to the challenges posed by ART is
contextualised in terms of the changing global political
economy.
Contemporary public health decision
making regarding ART
The current thinking around ART in South Africa has been
polarised into two camps.
On the anti-side sit a coalition of government and public
health officials who argue that ART is too expensive, too
complex or too toxic for South Africa’s health care
infrastructure to implement.
The pro-side has been dominated by a growing coalition of
treatment advocates such as the trade unions, religious
organisations, health workers and political parties. The basis of
this group’s argument is essentially a human rights one —
access to life-saving medication is a basic human right.
Unfortunately the public debate has been retarded by a focus
on marginal issues, such as drug toxicity. There has been little
constructive discussion between these opposing camps on the
two key issues of cost and efficacy. Where the pro-camp has
focused on efficacy and considered cost predominantly in
relation to individual input costs, the anti-campaign has dwelt
on total system costs under conditions of universal access and
uptake. 
The data showing the efficacy of ART in dramatically
reducing rates of death, opportunistic infections and
hospitalisations are incontrovertible.2,3 One of the few valid
counterarguments relates to the financing and infrastructure
required to establish a treatment programme. It is undeniable
that a ‘First-World’-type ART treatment programme would be
unaffordable to a country such as South Africa.  A recent
publication4 calculated that providing ART to all stage III and
IV AIDS patients would cost the country between R15 billion
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and R70 billion per year by 2010 (which translates into roughly
half to double the current health budget).  Is it appropriate,
then, to conclude on the basis of these and similar figures,5 as
was done in the abovementioned analysis, that ART, though
effective, is unaffordable to less developed countries? This
paper argues for an alternative response that seeks to balance
considerations of cost with those of efficacy within the
framework of a rationed ART programme.
Rationale for a limited ART
programme
Our previous paper on this topic5 showed that an adequately
rationed treatment programme could cost the state a small
fraction of the above figures (R407 million direct intervention
costs in 2007). If one included direct savings  the intervention
could actually be cost saving to the health budget. Using such
scaled-down costs and considering potential savings as a result
of treatment, we have already seen how the individual cost-
effectiveness of ART makes a strong case for its delivery. The
population benefits, however, make the case particularly
convincing.
Population-level benefits of ART
Treatment and prevention share effective synergies
There is a growing consensus that prevention and care are
inextricably linked.  Concentrating on prevention alone is
particularly inadequate in countries with high prevalence
epidemics. Programmes that only offer condoms or counsel
abstinence generally fail to penetrate the denial, inertia and
sense of hopelessness that accompanies death and dying.6
South Africa’s response to the epidemic continues to be
characterised by high population levels of denial. The extent of
this problem is demonstrated by a survey done in 2001 which
revealed that only 3% of South Africans believe that a family
member or friend is HIV-positive.7 This contrasts with
countries such as Uganda where the leadership has been
candid about the urgency of the problem and 87% of the
populace are of the opinion that either a family member or
friend is infected with HIV.8
One way of dealing with the denial/discrimination/
stigmatisation cycle would be to provide treatment for HIV,
thus transforming it from a condition which is perceived as a
death sentence, to one which is seen as a manageable chronic
illness. The offer of treatment also provides a direct incentive
for persons to be counselled and tested — an intervention
which has been shown to reduce risky behaviour and hence
HIV transmission.9
The director of Brazil’s HIV programme argues that the
provision of treatment in general, and ARVs in particular, has
been vital to creating the openness around HIV necessary to
slow its spread.10 Brazil’s epidemic in 1990 was at a similar
stage to South Africa’s. Twelve years later, we have an adult
seroprevalence 15 times that of Brazil.11,12
Two important conclusion arise.
1. Firstly, a seemingly expensive treatment intervention can
be cost saving in the long term if it significantly reduces levels
of population denial, encourages counselling and testing and
thereby significantly reduces the number of new infections.
2. Secondly, these population-level benefits of an ARV
treatment programme occur even if the ARV programme itself
is significantly rationed. Thus the state sector does not need to
promise to provide unlimited access to ARVs. Rather, it is only
necessary that the state is seen to be doing all it can, within its
constraints, to provide treatment in order to change the way
people see both the illness and the risk-benefit balance of HIV
testing. 
Beyond all or nothing — a new
rationing mechanism
The evidence presented so far should enable consensus on two
crucial points. Firstly, an ART programme with unlimited
access and no consideration of programme design (and most
especially input costs) is unaffordable to a developing country
such as South Africa. Secondly,  an adequately rationed and
pragmatically designed ART programme would not only be
cost-effective at an individual level, but vital to the success of
long-term prevention efforts. The central question this raises is
how we should determine what this ‘adequate rationing’
entails.
An overview of traditional rationing mechanisms
Traditional rationing and priority-setting mechanisms such as
those proposed by the WHO13 or standard health planning
texts,14 propose the evaluation of new interventions in terms of
certain entrenched criteria, the chief of which are cost
effectiveness and considerations of equity (Table I). The result
of applying these criteria is the creation of a package of
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Table I. Green’s criteria for prioritising health care interventions14
1. Cost benefit/effectiveness analysis
2. Technical, administrative and legal feasibility
3. Knock-on effects
4. Financial and resource availability
5. Long-term sustainability
6. Acceptability
7. Social, economic and political effects
8. Impact on equity
9. Gender effects
10. Environmental effects
11. Other developmental objectives
12. Ease of expansion from a pilot activity or project
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essential interventions that should be accessible to all
inhabitants of a country. This basket of interventions should
expand in accordance with national wealth. Thus, as far as
AIDS treatment is concerned, the WHO has divided
interventions into three categories for low-, medium- and high-
income countries.13 According to this schema, ART is only
regarded as appropriate for high-income countries. As already
discussed, this all-or-nothing approach is no longer a
sufficiently nuanced approach to rationing.  Public health
decision-making requires a methodology which is able to vary
input and total costs of new interventions to see if there is a
configuration of the intervention which would confer a net
benefit to the country concerned.  Before examining one such
methodology let us first look at the contextual changes that
have necessitated a new approach.   
Changes in global context necessitate a new
approach to rationing 
ART, at an annual cost of $11 000 per person,15 is clearly
unaffordable to the majority of the world’s population who live
on under $2 per day.16 This represents the first time that a
highly efficacious treatment for a mass condition, and one for
which there is no substitute, is unaffordable to the majority of
those afflicted by the condition. How did this situation arise?  
This state of affairs could be attributed to the conjunction of
three processes embedded in the new global political economy:
the rapid increase in intra- and international income
inequalities, the increasing power of transnational
pharmaceutical companies, and the extraordinary strength of
intellectual property rights as determined by the World Trade
Organisation.   
The widening income inequalities have meant that a large
majority of the pharmaceutical industry’s profits arise in the
First World and the prices of ARVs were therefore set relative
to the benefit they confer to this market. The 20-year patent
protection afforded by TRIPS (Trade-Related Intellectual
Property Rights) frees these companies from the threat of
competition and thereby enables them to charge exorbitant
prices.  Even at these prices, ART remains considerably more
cost-effective than common therapies such as beta-blockers for
hypertension in rich countries.17,18
If the public health community had merely accepted these
high prices, then ART would certainly have remained
unaffordable for the many high-prevalence and poor countries.
A key part of rationing in the new era is therefore exposing the
unfair pricing system and campaigning for alternative systems.
So far this pressure has yielded a crucial amendment to TRIPS19
which enables countries such as South Africa to import or
manufacture cheap generic ARVs at one-thirtieth of the price.
There is every reason to expect that generic prices could drop
considerably further once economies of scale develop.20 The
chosen planning approach would therefore anticipate
reasonable estimates of these price decreases. It would also be
important to ensure that the new rationing mechanism takes
adequate notice of the global inequalities which have given rise
to the difficulty for Third-World countries to fund ART. One
way to do this would be to negotiate with international bodies
such as the Global Fund for AIDS, Tuberculosis and Malaria
(GFATM) in such a way that the international body would
match the funding put in by the national government.
How could this planning approach work in practice?
The three interdependent dimensions of ART
rationing
We propose a system that would ration ART by simultaneous
consideration of five dimensions (Fig. 1).
Primary dimensions would be:
• A: numbers of persons who receive ART
• B: type (and hence unit cost) of ART offered
• C: total budget allocated to ART.
Secondary dimensions would be:
• D: the total spending on HIV care and prevention
• E: other health and social spending, i.e. allocative
implications of the spending.
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C: HAART
Expenditure
A: Numbers
on HAART
B: HAART programme
design policies
D: Total HIV budget
The ABC of rationing HAART
Prevention
Care
Key: The constituent variables of A, B and C
A) Rationing in terms of the numbers of clients on ARVs
• ARVs would only be available to the following clients
• Knowledge of HIV status
• In stage IV
• Live in a specified catchment area around one of the facilities offering 
ARVs
• Regularly attend infectious diseases clinic
• Meet clinical and biological criteria
• Meet social and adherence criteria
  
B) Rationing in terms of streamlining the type of ART programme offered
• The cost of ART could be limited via:
i. Use of generics
ii. Only offering first line
iii. Cut cost-ineffective tests
iv. Nurse driven
C) Rationing in terms of budgetary restraints
• Limit total cost to national fiscus according to what is affordable
• Aim for matched funding from business, global funding, etc.
In addition
D) Balancing HIV/A DS spending with other health spending
E) Balancing health spending with other social spending
Fig. 1. Dimensions of rationing in designing an ART programme.
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Each of these dimensions is a vital determinant of the ART
programme’s size and shape.   We argue that the key to the
successful rationing of ART lies in balancing these dimensions.
A successful balance cannot be accomplished by simply
calculating an optimal solution in one dimension and imposing
this solution onto the others. Thus we cannot start, as
traditional rationing systems would, by working out the
optimal ART treatment package (such as three tiers of triple
therapy) at conventional prices and then multiply this cost by
the total number of persons in stage III and IV. As already
demonstrated this produces an unaffordable figure. Instead,
the dimensions should be simultaneously optimised and, in an
iterative fashion, the calculation adjusted until an optimal
equilibrium is found. This rationed form of the intervention
can then be appraised for inclusion into the national health
service.
Numbers on treatment (A)
Part I of this series applies this process to South Africa in 2002.
It was proposed that initially, the central constraint would be
infrastructural rather than financial. Each province should,
however, be able to start two pilot ART programmes in 2002,
covering 1% of patients developing AIDS. This could be
gradually increased to cover close to 10% of patients
developing AIDS by 2007. 
Resource allocation (C), total HIV spending (D), and total
social spending (E)
An upper limit should be placed on C to ensure that ART does
not have a disproportionate impact on D and E. Dimensions D
and E are particularly important when dealing with a disease
such as HIV where consideration of both behaviour
modification and poverty relief are crucial components of a
successful response. ART should not swamp out other vital
health sector expenditure such as primary health care or key
social programmes aimed at poverty alleviation (e.g. a basic
income grant). Green’s14 criteria might assist in determining the
acceptability of the primary and secondary balance points
chosen between these different spending options. 
C was set at R500 million, both because this would allow the
most cost-effective form of ART (B) to be given to a feasible
number of clients (A) and because this would be affordable
within the constraints of current public health spending.
Current HIV expenditure is R5 - 8 billion per annum.21
Programme design (B)
In order for this budget to provide treatment to as many as
possible, B was configured in such a way as to minimise the
cost-ineffective components of ART.  Expensive laboratory tests
were foregone, generic drugs were used instead of patent
drugs and in the baseline scenario, ART was limited to a single
tier of triple therapy. This brought the costs per patient per
year down to R5 700. ART was also offered only to those in
stage IV. Many of these choices are very difficult to make. Both
limiting ART to a single tier of therapy and limiting it to
persons entering stage IV means offering each person with
AIDS a less than optimal form of ART. These steps do,
however, go a long way to ensuring that the limited budget can
provide ART to enough persons to make the programme
feasible.    
Most existing ART programmes are designed in such a way
that applicants for ART must pass through a selection process.
In the Medisins Sans Frontieres (MSF) Khayelitsha project for
example, biological and social criteria are used to select
patients. Despite being able to provide ART to just 4% of the
persons with AIDS in Khayelitsha, the programme is not
massively oversubscribed. The determination of how stringent
these criteria are, therefore, offers a further way of controlling
A (numbers on treatment). This is just one further example of
the importance of balancing these different dimensions using
an iterative approach.
Issues emerging from a pragmatic
iterative approach to rationing ART
Human rights response to rationing
The proposed approach to rationing must comply with the
imperatives of the South African Constitution, and in particular
the right of access to health care services.  The latter right is
expressly qualified by the availability of resources and subject
to progressive realisation. This provision has been applied by
the courts in the Soobramoney and Treatment Action
Campaign cases.  The court’s reasoning in these cases indicates
that the scarcity of resources as well as the context within
which health care services are rendered necessitates some form
of rationing. The court did note that the way the state rations
services must address the needs of the most marginalised.  In
addition, it has interpreted the right to health to mean
progressive realisation over time.  The rationing mechanisms
proposed in this paper are likely to accord with this standard.
Importance of broader societal acceptance of value
judgements
It would be misleading to suggest that such a complex
question as the makeup of a national AIDS programme could
be solved by a technocratic rationing mechanism alone. Many
of the decisions involve difficult value and technical
judgements.   An example of such value judgements is the
choice between treating a smaller number of persons with a
two-tier arsenal of therapy and treating a greater number of
persons with a single tier of ARVs (where the total benefit per
person would be less). The latter option was ultimately
favoured as this would benefit more persons (and hence confer
greater equity) and was more cost-effective (i.e. resulted in a
greater number of life-years gained per amount spent) than the
two-tier option. Many of the value judgements implicit in these
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assumptions may however be at odds with those of the general
populace. A central element of the decision-making process
should therefore be ensuring that all role players participate in
the process.
Conclusion — to accept that ART is
unaffordable to poor countries is to
accept the deepening of the system of
global apartheid
ART has been proved to be highly effective in prolonging the
lives of persons with AIDS. It is in addition a vital component
of the treatment programme so necessary to affect the
population level shifts in how this disease is perceived. At
First-World prices, however, it remains too expensive for
general roll-out in developing countries.   Public health needs
to develop a new methodology for rationing in resource-poor
settings which allows for a comprehensive response (including
ART) to challenges such as the one illustrated by HIV/AIDS in
many poor countries, while taking cognisance of the global
changes that have brought this situation about. The tentative
outline of one such methodology has been presented here in
response to the all-or-nothing approaches that have
characterised debates on ART. 
The relevance of developing novel approaches to resource
allocation mechanism is unlikely to be limited to ART. HIV is
but one of 30 infectious diseases that have emerged in the last
25 years, the majority of which place their greatest burden on
the poor.22 Our response to ART could therefore be crucial in
determining how we allow the global political economy to
unfold with regard to differential access to new therapies. 
The differential access to ART is a marker of the enormity of
the inequalities that have built up. Promoting access to ART
should therefore not be limited to wringing price concessions
out of pharmaceutical companies, but should be done in a way
that highlights the shortcomings of a system that has placed
such a large proportion of the global populace in a position of
extreme vulnerability to the human immunodeficiency virus
and cut them off from access to treatment. ART provides us
with an opportunity to expose the effects of this system to
those with the power to change it. To accept that drug
companies should be able to set the prices of life-saving
medications as they see fit and the consequent view that ART is
unaffordable to poor countries is to accept the deepening of the
system of global apartheid.
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